A geographic read on U.S. TMS activity (CPT 90867 / 90868 / 90869), built from all-payor claims on the Alpha Sophia platform. This brief shows the shape of the market — the full extract names every site.
Each tile is a state; darker tiles deliver more TMS. The pattern is what matters here — a dense western and coastal cluster, with a long tail of emerging markets. Hover any state for an approximate read. Clinic-level detail is reserved for the full extract.
The highest-volume individual TMS prescribers in the U.S. across CPT 90867, 90868 and 90869 — names anonymized. Specialty, practice, metro, per-code activity and year-over-year trend are shown; full identities (name, NPI, affiliation) and exact volumes are in the report.
Transcranial magnetic stimulation is a non-invasive, drug-free neurostimulation therapy delivered over repeated outpatient sessions — so a single course generates a long series of billable encounters. It sits at the intersection of three forces reshaping behavioral health: a large treatment-resistant patient pool, a widening set of FDA-cleared indications, and an increasingly favorable reimbursement story.
The demand driver. At least 30% of people treated with antidepressants don't respond adequately, and across U.S. payers the treatment-resistant share of medication-treated major depression runs from roughly one-fifth (Medicare) to over 40%. That is a large, underserved population for which TMS is an evidence-backed, guideline-supported next step.
The expansion driver. The indication envelope keeps widening: TMS is FDA-cleared for major depressive disorder and OCD, and in 2024–2025 clearances extended to adolescents (ages 15–21) and to accelerated protocols (SAINT-style) that compress an initial course from weeks into days — opening new site types and higher-throughput economics.
The reimbursement driver. Retrospective payer analyses show rTMS for treatment-resistant depression reduces high-acuity utilization and overall payer cost versus untreated patients — strengthening coverage and the case for capacity expansion.
Billing data tells you who delivers TMS today. The real white space is everyone who sees the patients but isn't capturing the procedure. Alpha Sophia layers diagnosis signals on top of procedure claims — so you can find practices and psychiatrists managing high volumes of TMS-eligible patients (treatment-resistant depression, MDD, OCD, heavy antidepressant management) who don't currently bill TMS, or who used to and stopped.
Practices with substantial TMS-eligible diagnosis volume but little or no TMS billing — greenfield targets for a device or new service line.
Sites that billed TMS historically but have gone quiet — prime reactivation and win-back candidates.
Markets with strong TMS-eligible diagnosis volume but few active TMS sites — where new capacity meets unmet demand.
Practices with a high volume of treatment-resistant depression and MDD diagnoses that are not currently billing any TMS codes — the clearest greenfield targets for a device or a new service line. Powered by the Alpha Sophia diagnosis-based demand layer.
See every clinic with high treatment-resistant depression diagnosis volume that isn’t billing TMS yet — ranked by opportunity, with names and locations.
Request pricing →This brief is a point-in-time read. The full report adds year-over-year TMS growth by state and by site — so you can see which markets are accelerating, which have plateaued, and where new patient starts are climbing fastest. Track momentum, not just today's leaderboard.
Get the year-over-year trend report →A transparent summary of the data, definitions and limitations behind the figures shown here.
Quick answers on U.S. TMS volume, billing codes, market size and how to get the underlying data.
Recent, credible references on the clinical evidence, regulatory expansion and the device landscape behind this market.
The teaser above shows the shape of the market. Here's everything the full U.S. TMS market report delivers.
All 2,469 organizations — name, NPI, parent health system, and full practice address (city / state / ZIP).
Exact procedure counts for CPT 90867, 90868 and 90869 at every site (all-payor), plus totals.
The complete ranked list of individual TMS-prescribing physicians (name, NPI, specialty, affiliation) — not just the anonymized top 8.
Affiliated HCP counts and Alpha Sophia profile links for each organization, for account planning.
Clinics with high TRD/MDD diagnosis volume and no TMS billing history, plus lapsed billers.
Year-over-year growth by state and site, CSV / XLSX (CRM-ready) export, refresh options and a usage license.
This brief shows the shape of the market. The full Alpha Sophia extract gives you the clinic-by-clinic detail — and the demand-vs-supply layer — your commercial team needs to build territories and target the right accounts.
Book an extract scoping call →Skip the call — email Isabel directly with your scope or questions, and we’ll get the right TMS extract priced and over to you.
This brief presents aggregated, approximate, state-level estimates derived from all-payor claims, for illustration. Figures are directional. CPT® is a registered trademark of the American Medical Association. Source: Alpha Sophia.